Major Diabetes Medication Shift Could Prevent Thousands of Deaths
A groundbreaking new study has revealed that a recently endorsed class of diabetes medication could prevent approximately 20,000 deaths each year in the United Kingdom. The research, conducted by experts from University College London and the London School of Hygiene & Tropical Medicine, analysed comprehensive data from 60,000 individuals across the UK.
Significant Reduction in Premature Mortality
The investigation focused on SGLT-2 inhibitor tablets, a once-daily medication that includes drugs such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. These medications function by assisting the kidneys in removing excess glucose from the bloodstream, which is subsequently expelled from the body through urine.
Researchers discovered that patients with type 2 diabetes who were prescribed SGLT-2 inhibitors demonstrated a remarkable 24 per cent reduction in premature death risk over an average three-year period when compared to those using alternative blood sugar-lowering treatments.
Wider Application Than Previously Understood
Dr David Ryan, a clinical pharmacology specialist and PhD student at the UCL Institute of Health Informatics, emphasised the broader implications of their findings. "Our study shows this drug works very well in a much wider range of people with type 2 diabetes than we previously had evidence for," he stated.
"Our findings support Nice's draft guidance proposing its use as a first treatment for type 2 diabetes, in addition to metformin – which would be a major shift in diabetes care affecting millions," Dr Ryan continued. "The typical person with type 2 diabetes may live longer with these tablets."
Aligning with National Health Guidelines
This research arrives following the National Institute for Health and Care Excellence's endorsement of SGLT-2 inhibitors as a first-line treatment option. In August, Nice announced what it described as the most significant transformation in diabetes care in a decade, promising earlier access to newer treatments for millions of patients.
Nice's own analysis of 590,000 patient records revealed that these medications remain under-prescribed, particularly among women, older individuals, and black patients. The new guidelines recommend that patients who cannot tolerate metformin – traditionally the first-choice medication for type 2 diabetes – should commence treatment with an SGLT-2 inhibitor as a standalone therapy.
Comprehensive Health Benefits Beyond Blood Sugar Control
Beyond their primary function of regulating blood glucose levels, evidence suggests that SGLT-2 inhibitors provide additional protective benefits for both cardiovascular and renal health. This dual-action approach represents a significant advancement in diabetes management.
Dr Patrick Bidulka of LSHTM highlighted the methodological importance of their research, published in BMJ Open Diabetes Research & Care. "This is a good example of how patient data can help inform patient care," he remarked. "It shows how we can use electronic health records safely to complement evidence from randomised controlled trials to improve outcomes for patients."
The Scale of Diabetes in the United Kingdom
The findings carry substantial weight given the prevalence of diabetes across the nation:
- Approximately 4.6 million people in the UK live with diabetes
- Nine out of ten diabetes cases involve type 2 diabetes
- An estimated 1.3 million additional individuals may have undiagnosed type 2 diabetes
- Roughly three million people currently receive treatment for type 2 diabetes
Based on this treatment population, researchers calculated that widespread adoption of SGLT-2 inhibitors could prevent around 20,000 deaths annually, marking a potential watershed moment in public health strategy for chronic disease management.
